NEW YORK (TheStreet) -- Sarepta Therapeutics (SRPT - Get Report) plunged Thursday after the company reported data from its Phase II study of eteplirsen, an experimental drug designed to treat Duchenne muscular dystrophy.
The data from 144 weeks of the study showed a greater decline in walking ability in patients treated with the drug compared to previous updates on the study. Sarepta still plans to file for FDA approval of eteplirsen by the end of the year.
Duchenne muscular dystrophy is a degenerative disease that causes patients to progressively lose muscle function and eventually leads to death.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts